Source: International Congress 2014 – Tuberculosis: diagnosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Mozhokina, N. Elistratova, I. Solovieva (Moscow, Russian Federation). Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity. Eur Respir J 2014; 44: Suppl. 58, 2590

Member's Comments

No comment yet.

Related content which might interest you: Rational use of new TB drugs in the EU Source: Annual Congress 2012 - New guidelines in respiratory infections Year: 2012 Neuroleptic drugs as potential adjuvants in the treatment of MDR-TB: Minimal inhibitory concentrations (MICs) of different phenothiazines against M. tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 New anti-tuberculosis drugs for special populations: a difficult-to-address issue Source: Eur Respir J 2016; 48: 957-958 Year: 2016 Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008 Confirmation of preclinical data on tioureidoiminomethylpyridinium perchlorate in treatment of MDR-TB Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Perspectives on the new drugs pipeline Source: School Course 13 Year: 2013 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Chloroquine as a potential adjunctive therapy in tuberculosis Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014 Drug resistant pattern of antitubercular drugs in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015 In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351) Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Management of COVID-19: Drugs anti-virals Source: ERS Course 2021 - COVID-19: State of the art Year: 2021 Impact of food intake on pharmacokinetics(PK) of first-line tuberculosis drugs in treatment-naive patients Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012